Key Developments: Galena Biopharma Inc (GALE.PH)

GALE.PH on Philadelphia Stock Exchange

2.33USD
29 Aug 2014
Price Change (% chg)

$-0.06 (-2.51%)
Prev Close
$2.39
Open
$2.34
Day's High
$2.35
Day's Low
$2.32
Volume
1,100
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Latest Key Developments (Source: Significant Developments)

Galena Biopharma appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
Thursday, 21 Aug 2014 07:05am EDT 

Galena Biopharma Inc:Appoints Mark W. Schwartz, Ph.D as President and Chief Executive Officer, effective immediately.Replaces Mark J. Ahn, Ph.D. who has resigned as the President and CEO and as a director.  Full Article

Galena Biopharma Inc maintains FY 2014 revenue guidance - Conference call
Monday, 11 Aug 2014 05:00pm EDT 

Galena Biopharma Inc:Maintains net revenue guidance of $11 mln to $15 mln for FY 2014, leaning towards lower end of that range.FY 2014 revenue of $14 mln - Thomson Reuters I/B/E/S.  Full Article

Galena Biopharma Inc enters into definitive agreement to license U.S. rights for Zuplenz (ondansetron) Oral Soluble Film
Tuesday, 22 Jul 2014 07:05am EDT 

Galena Biopharma Inc:Says it has entered into a definitive agreement to license the U.S. rights for the commercial product Zuplenz oral soluble film.The asset was licensed from MonoSol Rx, LLC, the developer of the oral soluble film technology, PharmFilm, and manufacturer of the product.Under the terms of the license agreement, upon effectiveness of the license and transfer to Galena of the New Drug Application (NDA) for Zuplenz, Galena will pay MonoSol Rx a total of $5,000,000 in cash and stock.The license agreement also provides for fixed double-digit royalties on net sales and pre-specified, one-time sales milestones.Zuplenz has issued and pending U.S. patent applications with an anticipated expiration date of 2029.Galena expects to launch Zuplenz in early 2015.  Full Article

Brower Piven announces filing of class action lawsuit against Galena BioPharma, Inc
Friday, 25 Apr 2014 01:39pm EDT 

Brower Piven:Announces that class action lawsuit has been commenced on behalf of purchasers of Galena Biopharma, Inc. common stock during the period between May 9, 2013 and March 17, 2014.Complaint alleges that throughout the class period defendants misrepresented and/or failed to disclose that it hired a promoter, The DreamTeam Group, to boost Galena's share price.Promoter posted misleading articles on Galena's behalf without properly disclosing its paid marketing relationship.As a result, its statements were materially false and misleading at all relevant times.  Full Article

Howard G. Smith files an expanded class period in shareholder lawsuit Galena Biopharma
Tuesday, 22 Apr 2014 10:32am EDT 

Howard G. Smith:Files class action lawsuit against Galena Biopharma, Inc. in the United States District Court for District of Oregon has been expanded to include all purchasers of Galena common stock between May 9, 2013 and March 17.Complaint alleges that throughout the Class Period defendants hired a promoter - The DreamTeam Group - to boost Galena's share price.Promoter posted misleading articles on Galena's behalf without properly disclosing its paid marketing relationship.  Full Article

Pomerantz Law Firm announces filing of class action against Galena Biopharma Inc and Certain Officers
Friday, 11 Apr 2014 04:14pm EDT 

Pomerantz LLP:Filed a class action lawsuit against Galena Biopharma, Inc.Complaint alleges that throughout the Class Period, Defendants orchestrated a scheme to increase the value of the Company's publicly traded stock so that insiders could reap the benefits by selling millions of dollars of shares of the Company's stock.Defendants made false and/or misleading statements and/or failed to disclose that Galena paid $50,000 to a subsidiary of The DreamTeam Group for 240 days of "advertising, branding, marketing, investor relations and social media services.Certain of DreamTeam's marketing tactics resembled stock promotion schemes which ran afoul of standard investor relations practices.DreamTeam published favorable articles about Galena on Seeking Alpha that failed to disclose that they were published by DreamTeam and instead appeared to be written from the perspective of individual investors recommending an investment in Galena.  Full Article

Galena Biopharma Inc gives FY 2014 revenue guidance in line with analysts' estimates - Conference call
Tuesday, 8 Apr 2014 08:40am EDT 

Galena Biopharma Inc:Says that it has guided the street to $11 mln to $15 mln in net revenues for fiscal 2014.Fiscal 2014 revenue estimate of $14 mln - Thomson Reuters I/B/E/S.  Full Article

Lieff Cabraser Heimann & Bernstein files class action litigation against Galena Biopharma Inc
Friday, 21 Mar 2014 09:00am EDT 

Lieff Cabraser Heimann & Bernstein LLP:Files class action litigation has been brought on behalf of those who purchased or otherwise acquired the securities of Galena Biopharma Inc., between May 9, 2013 and February 14, 2014, inclusive.Purchased or otherwise acquired Galena securities during the class period, you may move the Court for appointment as lead plaintiff by no later than May 5, 2014.Lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.  Full Article

Ryan & Maniskas, LLP announces class action lawsuit against Galena Biopharma, Inc
Wednesday, 19 Mar 2014 06:00pm EDT 

Ryan & Maniskas, LLP:Files a class action lawsuit against Galena Biopharma, Inc on behalf of a class comprising all purchasers of securities between Nov. 6, 2013 and Feb. 14.Complaint alleges that throughout the Class Period defendants misrepresented and/or failed to disclose that the company hired a promoter - The DreamTeam Group - to boost Galena's share price.The promoter posted misleading articles on Galena's behalf without properly disclosing its paid marketing relationship.As a result, the company's statements were materially false and misleading at all relevant times.  Full Article

Glancy Binkow & Goldberg LLP files class action lawsuit against Galena Biopharma, Inc
Tuesday, 11 Mar 2014 10:32am EDT 

Glancy Binkow & Goldberg LLP:Representing investors of Galena Biopharma, Inc filed a class action lawsuit in the United States District Court for the District of Oregon on behalf of a class comprising all purchasers of Galena securities between Nov. 6, 2013 and Feb. 14, inclusive.Complaint alleges that throughout the Class Period defendants misrepresented and/or failed to disclose that: it has hired a promoter The DreamTeam Group to boost Galena's share price and promoter posted misleading articles on Galena's behalf without properly disclosing its marketing relationship.  Full Article

Galena Biopharma shares fall after disclosure of SEC probe

March 18 - Shares of Galena Biopharma Inc fell as much as 21 percent on Tuesday after the company said the U.S. Securities and Exchange Commission was investigating its dealings with an external investor-relations firm.

Search Stocks